v3.26.1
STOCK-BASED COMPENSATION
3 Months Ended
Mar. 31, 2026
Compensation Related Costs [Abstract]  
STOCK-BASED COMPENSATION

NOTE 16STOCK-BASED COMPENSATION

 

Pursuant to the Company’s 2025 Omnibus Equity Incentive Plan adopted and approved in 2025 (“2025 Plan”), awards under the 2025 Plan are limited in the aggregate to 2,000,000 shares of our common stock, inclusive of the awards that were previously issued and outstanding under the Company’s 2019 Omnibus Equity Incentive Plan,, as amended (the “2019 Plan”). Upon adoption and approval of the 2025 Plan, the 2019 Plan was frozen, no new awards will be granted under the 2019 Plan, and outstanding awards under the 2019 Plan will continue to be governed by the terms and condition of the 2019 Plan and applicable award agreement. As of March 31, 2026, the number of shares of the Company’s common stock available for grant of stock options and issuance under the 2025 Plan is 14,000 shares.

 

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The risk free rate is based on the yield-to-maturity in continuous compounding of the US Government Bonds with the time-to-maturity similar to the expected tenor of the option granted, volatility is based on the annualized historical stock price volatility of the Company, and the expected life is based on the historical option exercise pattern.

 

For the three months ended March 31, 2026 and 2025, total compensation costs for options issued recorded in the consolidated statement of comprehensive income (loss) were nil. There were no related tax benefits as a full valuation allowance was recorded in the three months ended March 31, 2026 and 2025.

 

The following table summarizes all Company stock option transactions between January 1, 2026 and March 31, 2026.

    Number of Option and Warrants Outstanding and exercisable    Weighted- Average Exercise price of Option and Warrants    Range of Exercise Price per Common Share 
Balance, January 1, 2026      $     
Granted during the period            
Exercised during the period            
Expired during the period      $   $ 
Balance, March 31, 2026      $     

 

 

   Stock Options and Warrants Outstanding and Exercisable     
    

Outstanding at

March 31, 2026

    

Range of

Exercise Prices

    

Weighted Average Remaining Contractual Life

(Years)

 
Outstanding and exercisable            

 

 

All options exercisable and outstanding as at March 31, 2026 are fully vested. As of March 31, 2026 there was no unrecognized compensation cost related to outstanding stock options.

 

The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2026, was nil .

 

During the three months ended March 31, 2026 and 2025, there were no options exercised.